1. Latest News
  2. Submit Press Release

NAPSR news: Gilead reveals 2014 Q2 Report, sales soar for blockbuster drug Sovaldi

Gilead Sciences, Inc. is a biopharmaceutical company whose main focus is centered on discovering, developing and commercializing innovative therapeutics in areas of unmet medical need.

PRLog - July 25, 2014 - WASHINGTON -- With the announcement of the Gilead’s Q2 report, the company had a record breaking quarter as the total revenues increased to $6.53 billion compared to $2.77 billion for the second quarter of 2013.  Net income for the second quarter of 2014 totaled $3.66 billion, or $2.20 per diluted share compared to $772.6 million or $0.46 per diluted share for the second quarter of 2013.

Gilead’s blockbuster drug Sovaldi made an impressive contribution with sales amounting to $3.48 billion, bringing its total revenues since the beginning of the year to over $5.75 billion. Though the drug has faced criticism over its price, Gilead has come to its defense citing that Sovaldi is a lifetime treatment option that have cured patients quickly that other therapies and will also steer them from additional costs that may arise from other pricey treatment options. For instance, liver transplants and other expensive consequences of Hep C infection.

“During the second quarter, Gilead continued to make significant progress led by strong Sovaldi sales. Since December’s launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical community’s recognition of the benefits of this product,” said John C. Martin, PhD, Gilead’s Chairman and Chief Executive Officer. “We look forward to making Sovaldi available in additional countries.”

With such industry leaders posting gains in profitability from their successful product pipeline, they will need both certified and qualified individuals to promote their diversified therapeutic portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.


--- End ---

Click to Share

Contact Email:
***@napsronline.org Email Verified
Location:Washington - District of Columbia - United States
Industry:Biotech, Health
Tags:napsrx, cnpr certification, pharmaceutical sales, naprx, sales representatives
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

Like PRLog?
Click to Share